
Cornelis H Van Werkhoven

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2694623/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Five versus seven days of nitrofurantoin for urinary tract infections in women with diabetes: a retrospective cohort study. Clinical Microbiology and Infection, 2022, 28, 377-382.	6.0	Ο
2	Fosfomycin Vs Ciprofloxacin as Oral Step-Down Treatment for <i>Escherichia coli</i> Febrile Urinary Tract Infections in Women: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Clinical Infectious Diseases, 2022, 75, 221-229.	5.8	9
3	Does plasmid-based beta-lactam resistance increase E. coli infections: Modelling addition and replacement mechanisms. PLoS Computational Biology, 2022, 18, e1009875.	3.2	1
4	An International Prospective Cohort Study To Validate 2 Prediction Rules for Infections Caused by Third-generation Cephalosporin-resistant Enterobacterales. Clinical Infectious Diseases, 2021, 73, e4475-e4483.	5.8	2
5	Effects of 13-valent pneumococcal conjugate vaccination of adults on lower respiratory tract infections and antibiotic use in primary care: secondary analysis of a double-blind randomized placebo-controlled study. Clinical Microbiology and Infection, 2021, 27, 995-999.	6.0	11
6	Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics. Nature Communications, 2021, 12, 2240.	12.8	21
7	Microbiota-based markers predictive of development of Clostridioides difficile infection. Nature Communications, 2021, 12, 2241.	12.8	40
8	Effects of 13-valent pneumococcal conjugate vaccination of adults on lower respiratory tract infections and antibiotic use in primary care: authors' response. Clinical Microbiology and Infection, 2021, 27, 926.	6.0	0
9	The prognostic value of serological titres for clinical outcomes during treatment and follow-up of patients with chronic Q fever. Clinical Microbiology and Infection, 2021, 27, 1273-1278.	6.0	9
10	Safety and COVID-19 Symptoms in Individuals Recently Vaccinated with BCG: a Retrospective Cohort Study. Cell Reports Medicine, 2020, 1, 100073.	6.5	78
11	Impact of antimicrobial de-escalation on mortality: a literature review of study methodology and recommendations for observational studies. Expert Review of Anti-Infective Therapy, 2020, 18, 405-413.	4.4	4
12	A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands. Vaccine, 2019, 37, 5777-5787.	3.8	41
13	Effectiveness of extended- versus normal-release nitrofurantoin for cystitis: an instrumental variable analysis. Journal of Antimicrobial Chemotherapy, 2019, 74, 3337-3343.	3.0	5
14	Confounding by indication of the safety of de-escalation in community-acquired pneumonia: AÂsimulation study embedded in a prospective cohort. PLoS ONE, 2019, 14, e0218062.	2.5	7
15	How fluoroquinolones poison the neighbourhood. Lancet Infectious Diseases, The, 2019, 19, 347-348.	9.1	0
16	Cost-effectiveness of selective digestive decontamination (SDD) versus selective oropharyngeal decontamination (SOD) in intensive care units with low levels of antimicrobial resistance: an individual patient data meta-analysis. BMJ Open, 2019, 9, e028876.	1.9	12
17	Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial. BMC Infectious Diseases, 2019, 19, 17.	2.9	29
18	Inappropriate Use of Antimicrobials for Lower Respiratory Tract Infections in Elderly Patients: Patient- and Community-Related Implications and Possible Interventions. Drugs and Aging, 2018, 35, 389-398.	2.7	7

#	Article	IF	CITATIONS
19	Vaccines to Prevent Pneumococcal Community-Acquired Pneumonia. Clinics in Chest Medicine, 2018, 39, 733-752.	2.1	21
20	Cost-effectiveness of antibiotic treatment strategies for community-acquired pneumonia: results from a cluster randomized cross-over trial. BMC Infectious Diseases, 2017, 17, 52.	2.9	9
21	Post-hoc analysis of a randomized controlled trial: Diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly. Vaccine, 2017, 35, 4444-4449.	3.8	38
22	Response Adjusted for Days of Antibiotic Risk (RADAR): evaluation of a novel method to compare strategies to optimize antibiotic use. Clinical Microbiology and Infection, 2017, 23, 980-985.	6.0	8
23	Community-acquired pneumonia requiring hospitalization. Current Opinion in Pulmonary Medicine, 2017, 23, 204-210.	2.6	7
24	Herd effects of child vaccination with pneumococcal conjugate vaccine against pneumococcal non-invasive community-acquired pneumonia: What is the evidence?. Human Vaccines and Immunotherapeutics, 2017, 13, 1177-1181.	3.3	8
25	Do admission glucose levels aid in predicting mortality associated with community-acquired pneumonia?. European Respiratory Journal, 2017, 50, 1700307.	6.7	4
26	Atypical coverage in community-acquired pneumonia after outpatient beta-lactam monotherapy. Respiratory Medicine, 2017, 129, 145-151.	2.9	1
27	Quality of life in community-dwelling Dutch elderly measured by EQ-5D-3L. Health and Quality of Life Outcomes, 2017, 15, 3.	2.4	38
28	Pneumococcal conjugate vaccine herd effects on non-invasive pneumococcal pneumonia in elderly. Vaccine, 2016, 34, 3275-3282.	3.8	28
29	Management of Community-Acquired Pneumonia. JAMA - Journal of the American Medical Association, 2016, 316, 221.	7.4	1
30	The scrutiny of identifying community-acquired pneumonia episodes quantified bias in absolute effect estimation in a population-based pneumococcal vaccination trial. Journal of Clinical Epidemiology, 2016, 69, 185-192.	5.0	7
31	Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. European Respiratory Journal, 2015, 46, 1407-1416.	6.7	92
32	Identification of patients at high risk for Clostridium difficile infection: development and validation of a risk prediction model in hospitalized patients treated with antibiotics. Clinical Microbiology and Infection, 2015, 21, 786.e1-786.e8.	6.0	21
33	Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults. New England Journal of Medicine, 2015, 372, 1114-1125.	27.0	957
34	Antibiotic Treatment Strategies for Community-Acquired Pneumonia in Adults. New England Journal of Medicine, 2015, 372, 1312-1323.	27.0	296
35	The Impact of Age on the Efficacy of 13-valent Pneumococcal Conjugate Vaccine in Elderly. Clinical Infectious Diseases, 2015, 61, 1835-1838.	5.8	64
36	The Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA): what is the future of pneumococcal conjugate vaccination in elderly?. Future Microbiology, 2015, 10, 1405-1413.	2.0	12

#	Article	IF	CITATIONS
37	Predictors of Bacteraemia in Patients with Suspected Community-Acquired Pneumonia. PLoS ONE, 2015, 10, e0143817.	2.5	13
38	109913-valent Pneumococcal Conjugate Vaccine Efficacy is Declining with Old Age: Results from an Exploratory Analysis of the CAPiTA Trial. Open Forum Infectious Diseases, 2014, 1, S324-S325.	0.9	1
39	Rapid Systematic Review of the Epley Maneuver versus Vestibular Rehabilitation for Benign Paroxysmal Positional Vertigo. Otolaryngology - Head and Neck Surgery, 2014, 151, 201-207.	1.9	8
40	The immunomodulatory effects of statins in community-acquired pneumonia: A systematic review. Journal of Infection, 2013, 67, 93-101.	3.3	26
41	Observed Mortality Reduction in Patients Hospitalized with Community-acquired Pneumonia May Well Be Confounded by Disease Severity. American Journal of Medicine, 2013, 126, e23.	1.5	0
42	Predicting Community-Acquired Pneumonia Etiology. Chest, 2013, 144, 1975-1976.	0.8	0